Literature DB >> 1385624

Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.

M F Beal1, W R Matson, E Storey, P Milbury, E A Ryan, T Ogawa, E D Bird.   

Abstract

Huntington's disease (HD) is characterized by gradually evolving selective neuronal death. Several lines of evidence suggest that an excitotoxic mechanism may play a role. Tryptophan metabolism leads to production of quinolinic acid, an N-methyl-D-aspartate (NMDA) receptor agonist, and to kynurenic acid, an antagonist at these same receptors. We recently found increased kynurenine to kynurenic acid ratios in HD postmortem putamen and decreased kynurenic acid concentrations in cerebrospinal fluid, consistent with decreased formation of kynurenic acid in HD brain. In the present study we used HPLC with 16 sensor coulometric electrochemical detection to measure kynurenic acid and 18 other electrochemically active compounds in 6 cortical regions, caudate and cerebellum from controls, HD, Alzheimer's disease (AD), and Parkinson's disease (PD) patients. Significant reductions in kynurenic acid concentrations were found in 5 of 6 cortical regions examined. Smaller reductions of kynurenic acid in the caudate, cerebellum and frontal pole were not significant. No significant reductions were found in the AD and PD patients. Both uric acid and glutathionine were significantly reduced in several regions of HD cerebral cortex, which could signify abnormal energy metabolism in HD. Since kynurenic acid is an antagonist of excitatory amino acid receptors, a deficiency could contribute to the pathogenesis of neuronal degeneration in HD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385624     DOI: 10.1016/0022-510x(92)90191-m

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  70 in total

1.  Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Howard M Eisenberg; Yasushi Kajii; Robert Schwarcz; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

Review 2.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

3.  Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice.

Authors:  Paul B Larkin; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Hiroshi Funakoshi; Toshikazu Nakamura; Robert Schwarcz; Paul J Muchowski
Journal:  Biochim Biophys Acta       Date:  2016-07-05

4.  Metabolomic applications of electrochemistry/mass spectrometry.

Authors:  Paul H Gamache; David F Meyer; Michael C Granger; Ian N Acworth
Journal:  J Am Soc Mass Spectrom       Date:  2004-12       Impact factor: 3.109

5.  Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93).

Authors:  Katarzyna Wejksza; Wojciech Rzeski; Etsuo Okuno; Martyna Kandefer-Szerszen; Jan Albrecht; Waldemar A Turski
Journal:  Neurochem Res       Date:  2005-08       Impact factor: 3.996

Review 6.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 7.  Structure, expression, and function of kynurenine aminotransferases in human and rodent brains.

Authors:  Qian Han; Tao Cai; Danilo A Tagle; Jianyong Li
Journal:  Cell Mol Life Sci       Date:  2009-10-15       Impact factor: 9.261

8.  Urinary kynurenine as a biomarker for Parkinson's disease.

Authors:  Jia-He Bai; Ya-Li Zheng; Yong-Peng Yu
Journal:  Neurol Sci       Date:  2020-07-13       Impact factor: 3.307

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.